Displaying drugs 10801 - 10825 of 12697 in total
(1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene
(1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene is a solid. This compound belongs to the naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings. Known drug targets of (1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene include naphthalene 1,2-dioxygenase subunit beta and naphthalene 1,2-dioxygenase subunit alpha.
Experimental
Matched Description: … These are compounds containing a naphthalene moiety, which consists of two fused benzene rings. ... Known drug targets of (1R, 2S)-cis 1,2 dihydroxy-1,2-dihydronaphthalene include naphthalene 1,2-dioxygenase …
SPL84-23-1
SPL84-23-1 is a sodium salt of 19-bp single-stranded RNA uniformly modified 2'-O-(2-methoxyethyl) phosphorothioate Antisense Oligonucleotide (ASO) consisting of 19 nucleotide residues with the sequence 5'-5MeC-5MeU-G-5MeC-A-A-5MeC-A-G-A-5MeU-G-G-A-A-G-A-5MeC-5MeU-3'
Investigational
Matched Description: … Antisense Oligonucleotide (ASO) consisting of 19 nucleotide residues with the sequence 5'-5MeC-5MeU-G ... SPL84-23-1 is a sodium salt of 19-bp single-stranded RNA uniformly modified 2'-O-(2-methoxyethyl) phosphorothioate …
NS-398
NS-398 is a COX-2 inhibitor. It was developed as part of the mechanistic study of the cyclooxygenases.
Experimental
Matched Description: … It was developed as part of the mechanistic study of the cyclooxygenases. …
Tridihexethyl
Tridihexethyl is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. Tridihexethyl is an antimuscarinic, anticholinergic drug. Tridihexethyl is no longer available in the US market.
Withdrawn
XAV-19
XAV-19 is an intravenous antibody-based treatment targeted towards SARS-CoV-2 and other coronaviruses[L16553,L16558]. The therapy concept is based on COVID-19 convalescent plasma. However, rather than using human plasma, XAV-19 is a heterologous swine glyco-humanized polyclonal antibody that targets the spike protein of SARS-CoV-2[L16553,L16558]. The therapy offers three beneficial effects: the ability...
Investigational
Matched Description: … and efficacy of XAV-19 (NCT04453384). ... , XAV-19 is a heterologous swine glyco-humanized polyclonal antibody that targets the spike protein of ... As of July, 2020, the company is conducting a Phase 2 randomized clinical trial to define dosing safety …
AT1022
AT1022 is a hydromorphone skin patch designed to provide rapid and sustained delivery of a potent opiate for the management of severe pain.
AT1022 incorporates PassPort(TM) system, developed to deliver protein and peptide drugs, small-molecule drugs, genes and vaccines across the skin for local and systemic effect.
Investigational
Matched Description: … for the management of severe pain. ... AT1022 is a hydromorphone skin patch designed to provide rapid and sustained delivery of a potent opiate …
IDD-1
Lipids promote the fusion of liposomes to cells. Eladem (IDD-1) is a therapeutic vaccine consisting of dendritophages that are loaded in vitro with tumor antigens and then reinjected into the subject. As with other monoclonal antibodies, this process stimulates an immune response to a particular disease-related antigen.
Investigational
Matched Description: … Lipids promote the fusion of liposomes to cells. ... Eladem (IDD-1) is a therapeutic vaccine consisting of dendritophages that are loaded in vitro with tumor …
OSI-7904L
OSI-7904L is a liposome encapsulated thymidylate synthase inhibitor, which is indicated for use in advanced gastric and/or gastroesophageal adenocarcinoma (A-G/GEJA). Current treatments also inhibit thymidylate synthase but the innovative lipid coating of OSI-7904L allows for more enduring results with administration of the TS inhibitor.
Investigational
Matched Description: … for more enduring results with administration of the TS inhibitor. ... Current treatments also inhibit thymidylate synthase but the innovative lipid coating of OSI-7904L allows …
TB-402
TB-402 is a human antibody binding to Factor VIII, which plays a crucial role in the coagulation of the blood. It is expected to be developed as a potential treatment to prevent blood clot formation in connection with certain types of heart arrhythmia, such as atrial fibrillation.
Investigational
Matched Description: … TB-402 is a human antibody binding to Factor VIII, which plays a crucial role in the coagulation of the ... developed as a potential treatment to prevent blood clot formation in connection with certain types of …
Myrcludex B
Myrcludex B is under investigation in clinical trial NCT03546621 (A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D).
Investigational
Matched Description: … trial NCT03546621 (A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of ... 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress …
Grn163l
GRN163L is a novel anti-cancer drug. It has been characterized preclinically and shown to inhibit telomerase in human tumor cells of many cancer types (including lung, breast, prostate, liver, and early stage of human breast cancer), in both cell culture systems and animal models. Study of this drug shows the...
Investigational
Matched Description: … Study of this drug shows the its potential utility in the treatment of patients with hematologic and ... It has been characterized preclinically and shown to inhibit telomerase in human tumor cells of many ... cancer types (including lung, breast, prostate, liver, and early stage of human breast cancer), in both …
Esmirtazapine
Esmirtazapine, known by the standardized identifier SCH 900265, was under development by Organon to treat insomnia and vasomotor symptoms associated with menopause. Esmirtazapine is the (S)-(+)-enantiomer of mirtazapine and possesses similar overall pharmacology. This includes inverse agonist activity of H1 and 5-HT2 receptors and antagonism of α2-adrenergic receptors. Merck has...
Investigational
Matched Description: … This includes inverse agonist activity of H1 and 5-HT2 receptors and antagonism of α2-adrenergic receptors ... Esmirtazapine is the (S)-(+)-enantiomer of mirtazapine and possesses similar overall pharmacology. ... Merck has terminated its internal clinical development program for esmirtazapine as of March 2010. …
Zanidatamab
According to Zymeworks, "ZW25 is a bispecific antibody that can simultaneously bind two non-overlapping epitopes, known as biparatopic binding, of HER2 resulting in dual HER2 signal blockade, increased binding and removal of HER2 protein from the cell surface, and potent effector function. These combined mechanisms of action have led to...
Investigational
Matched Description: … of breast and gastric cancers." ... HER2 resulting in dual HER2 signal blockade, increased binding and removal of HER2 protein from the ... These combined mechanisms of action have led to significant anti-tumor activity in preclinical models …
R1204
R1204 is G-protein-coupled receptor modulator. It is developed for the treatment of depression.
Investigational
Matched Description: … It is developed for the treatment of depression. …
Atacicept
Atacicept is a recombinant fusion protein combined with the extracellular ligand binding portion of TACI.
Investigational
Matched Description: … Atacicept is a recombinant fusion protein combined with the extracellular ligand binding portion of TACI …
Dapivirine
Dapivirine has been investigated for the prevention of HIV-1 Infections and Topical Penile Exposures.
Investigational
Matched Description: … Dapivirine has been investigated for the prevention of HIV-1 Infections and Topical Penile Exposures. …
Solanezumab
Solanezumab is under investigation for the treatment of Dementia, Alzheimers Disease, and Alzheimers Disease, Familial.
Investigational
Matched Description: … Solanezumab is under investigation for the treatment of Dementia, Alzheimers Disease, and Alzheimers …
Idalopirdine
Idalopirdine has been used in trials studying the treatment of Cognition, Schizophrenia, and Alzheimer's Disease.
Investigational
Matched Description: … Idalopirdine has been used in trials studying the treatment of Cognition, Schizophrenia, and Alzheimer's …
Ulinastatin
Ulinastatin has been investigated for the prevention of Cardiovascular Disease and Adverse Reaction to Drug.
Investigational
Matched Description: … Ulinastatin has been investigated for the prevention of Cardiovascular Disease and Adverse Reaction to …
Zamicastat
Zamicastat has been used in trials studying the treatment of Hypertension and Chronic Heart Failure.
Investigational
Matched Description: … Zamicastat has been used in trials studying the treatment of Hypertension and Chronic Heart Failure. …
Calcitonin eel
HC-58 has been used in trials studying the prevention of Severe Upper Limb Hemiplegia.
Investigational
Matched Description: … HC-58 has been used in trials studying the prevention of Severe Upper Limb Hemiplegia. …
Urocortin-2
Urocortin 2 has been investigated for the basic science of Heart Failure and Cardiovascular Disease.
Investigational
Matched Description: … Urocortin 2 has been investigated for the basic science of Heart Failure and Cardiovascular Disease. …
Thyrotropin
Thyrotropin is under investigation in clinical trial NCT01348191 (Detection of Thyrotrophin Receptor in Human Myometrium).
Investigational
Matched Description: … Thyrotropin is under investigation in clinical trial NCT01348191 (Detection of Thyrotrophin Receptor …
Petesicatib
Petesicatib is under investigation in clinical trial NCT02295332 (A Study of RG7625 in Healthy Volunteers).
Investigational
Matched Description: … Petesicatib is under investigation in clinical trial NCT02295332 (A Study of RG7625 in Healthy Volunteers …
KW-6356
KW-6356 is a selective antagonist of adenosine A2A receptors developed by Kyowa Kirin.
Experimental
Matched Description: … KW-6356 is a selective antagonist of adenosine A2A receptors developed by Kyowa Kirin.[L43822] …
Displaying drugs 10801 - 10825 of 12697 in total